Global Infectious Vaccines Market Size, Trends & Analysis - Forecasts to 2027 By Technology (Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, Toxoid vaccines Viral vector vaccines, and COVID-19 Vaccines) By Type (Monovalent vaccines and Multivalent vaccines) By Disease Indication (Influenza, Pneumococcal diseases, Combination vaccines, HPV, Herpes Zoster, Meningococcal diseases, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, COVID 19, and Other disease indications), By Route of Administration (Intramuscular & Subcutaneous administration, Oral administration and Other routes of administration) By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Company Market Share Analysis, and Competitor Analysis
The global infectious vaccines market is projected to grow at a CAGR value of 12.5% from 2022 to 2027.
The major driving factors likely to propel market expansion are increasing infectious diseases, increasing health awareness and emphasis on the effectiveness of vaccines, and growing population leading to increasing demand for contagious diseases.
Moreover, increasing research and development for building up vaccines compatible with the mutated diseases or viruses, rising concern as the infectious disease's prevalence is growing in poor and developing countries, and increasing investment to promote technological and medical advancement in the field by various stakeholders such as hospitals, research institutions, international organizations, and government is propelling the market growth.
Inadequate vaccination coverage and expensive shipping and storage expenses will stymie the industry's expansion in the future years.
The COVID-19 pandemic has positively impacted the infectious vaccines market growth. Due to the COVID-19 pandemic, most healthcare, pharmaceutical, and biotechnology companies have focused on diagnostic kits, safety wearables, and novel coronavirus treatment vaccines and medications. The Covid-19 outbreak prompted an increase in business funding and R&D operations for vaccines and treatments to combat the new coronavirus. Governments worldwide, as well as the World Health Organization (WHO), are working towards expanding the potential for vaccine production and worldwide supply.
Based on technology, the infectious vaccines market is divided into the following segments that are conjugate vaccines, inactivated & subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, viral vector vaccines, and COVID-19 vaccines.
The COVID-19 vaccines segment will have the largest share of the market during the forecast period as per the technology outlook. The rising and prevalence of COVID-19 coupled with rising population is expected to propel market growth for COVID -19 vaccines segment.
Based on type, the market is divided into monovalent vaccines and multivalent vaccines. Multivalent segment will be the fastest growing segment in the market during the forecast period. The growth of the segment can be ascribed to the rising occurrence of emerging and re-emerging infectious diseases, as well as R&D initiatives. Complex diseases such as malaria and HIV may benefit from future multivalent vaccines.
The infectious vaccines market has been segmented as influenza, pneumococcal diseases, combination vaccines, HPV, herpes zoster, meningococcal diseases, rotavirus, MMR, varicella, hepatitis, DTP, polio, COVID 19, and other disease indications (cancer, dengue, tuberculosis, typhoid, Japanese encephalitis, rabies, yellow fever, and allergies) based on disease indication.
The pneumococcal diseases segment is expected to hold the largest share of the market during the forecast period. The high frequency of pneumococcal illness and increasing government investments in pneumococcal vaccination programmes are responsible for the considerable representation of this category.
Based on route of administration, the market is divided into intramuscular & subcutaneous administration, oral administration, and other routes of administration (intranasal, intradermal, and percutaneous).
Intramuscular & subcutaneous administration segment is expected to hold largest share of market during the forecasted period. Because of the exact control of dose and administration rate, quick antigen exposure, and convenience of administration will lead to market dominance.
As per the geographical analysis, the global infectious vaccines market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America).
North America (the United States, Canada, and Mexico) region is expected to be the dominant force in the market during the forecasted period. The primary drivers contributing to market expansion are a steady rise in infectious disease in recent times, a sturdy healthcare system, and increased health awareness among the public. Measures by private corporations and the government have resulted in market expansion, and this trend is expected to continue in the forecast period.
Moreover, the Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific) region is expected to become the fastest-growing segment during the forecasted period. Many countries in the region have been urged to adopt suitable measures due to expanding population and the necessity for a robust healthcare system. The corporate and governmental sectors have made significant investments in improving their healthcare infrastructure and functioning, resulting in a surge in demand for infectious. Companies manufacturing infectious vaccines are becoming more prevalent in the Asia Pacific region.
The key players are GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax, Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals, Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), and Indian Immunologicals Limited (India), among others.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Infectious Vaccines Industry Overview, 2022-2027
2.1.1 Industry Overview
2.1.2 Technology Overview
2.1.3 Type Overview
2.1.4 Disease Indication Overview
2.1.5 Route of Administration Overview
2.1.6 Regional Overview
Chapter 3 Infectious Vaccines Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2022-2027
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Increasing Infectious Diseases
3.3.1.2 Increasing Health Awareness and Emphasis on The Effectiveness Of Vaccines
3.3.2 Industry Challenges
3.3.2.1 Inadequate Vaccination Coverage and Expensive Shipping and Storage Expenses Will Be Significant Challenge
3.4 Prospective Growth Scenario
3.4.1 Technology Growth Scenario
3.4.2 Type Growth Scenario
3.4.3 Disease Indication Growth Scenario
3.4.4 Route of Administration Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 End-User Overview
3.11 Market Share Analysis, 2021
3.11.1 Company Positioning Overview, 2021
Chapter 4 Infectious Vaccines Market, By Technology
4.1 Technology Outlook
4.2 Conjugate Vaccines
4.2.1 Market Size, By Region, 2022-2027 (USD Billion)
4.3 Inactivated & Subunit Vaccines
4.3.1 Market Size, By Region, 2022-2027 (USD Billion)
4.4 Live Attenuated Vaccines
4.4.1 Market Size, By Region, 2022-2027 (USD Billion)
4.5 Recombinant Vaccines
4.5.1 Market Size, By Region, 2022-2027 (USD Billion)
4.6 Toxoid Vaccines
4.6.1 Market Size, By Region, 2022-2027 (USD Billion)
4.7 Viral Vector Vaccines
4.7.1 Market Size, By Region, 2022-2027 (USD Billion)
4.8 COVID-19 Vaccines
4.8.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 5 Infectious Vaccines Market, By Disease Indication
5.1 Disease Indication Outlook
5.2 Influenza
5.2.1 Market Size, By Region, 2022-2027 (USD Billion)
5.3 Pneumococcal Diseases
5.3.1 Market Size, By Region, 2022-2027 (USD Billion)
5.4 Combination Vaccines
5.4.1 Market Size, By Region, 2022-2027 (USD Billion)
5.5 HPV
5.5.1 Market Size, By Region, 2022-2027 (USD Billion)
5.6 Herpes Zoster
5.6.1 Market Size, By Region, 2022-2027 (USD Billion)
5.7 Meningococcal Diseases
5.7.1 Market Size, By Region, 2022-2027 (USD Billion)
5.8 Rotavirus
5.8.1 Market Size, By Region, 2022-2027 (USD Billion)
5.9 MMR
5.9.1 Market Size, By Region, 2022-2027 (USD Billion)
5.10 Varicella
5.10.1 Market Size, By Region, 2022-2027 (USD Billion)
5.11 Hepatitis
5.11.1 Market Size, By Region, 2022-2027 (USD Billion)
5.12 DTP
5.12.1 Market Size, By Region, 2022-2027 (USD Billion)
5.13 Polio
5.13.1 Market Size, By Region, 2022-2027 (USD Billion)
5.14 COVID 19
5.14.1 Market Size, By Region, 2022-2027 (USD Billion)
5.15 Others
5.15.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 6 Infectious Vaccines Market, By Type
6.1 Monovalent Vaccines
6.1.1 Market Size, By Region, 2022-2027 (USD Billion)
6.2 Multivalent Vaccines
6.2.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 7 Infectious Vaccines Market, By Route of Administration
7.1 Intramuscular & Subcutaneous Administration
7.1.1 Market Size, By Region, 2022-2027 (USD Billion)
7.2 Oral Administration
7.2.1 Market Size, By Region, 2022-2027 (USD Billion)
7.3 Other Routes of Administration
7.3.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 8 Infectious Vaccines Market, By Region
8.1 Regional outlook
8.2 North America
8.2.1 Market Size, By Country 2022-2027 (USD Billion)
8.2.2 Market Size, By Technology, 2022-2027 (USD Billion)
8.2.3 Market Size, By Type, 2022-2027 (USD Billion)
8.2.4 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.2.5 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.2.6 U.S.
8.2.6.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.2.4.2 Market Size, By Type, 2022-2027 (USD Billion)
8.2.4.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.2.7 Canada
8.2.7.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.2.7.2 Market Size, By Type, 2022-2027 (USD Billion)
8.2.7.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.2.7.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3 Europe
8.3.1 Market Size, By Country 2022-2027 (USD Billion)
8.3.2 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.3 Market Size, By Type, 2022-2027 (USD Billion)
8.3.4 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.5 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.6 Germany
8.3.6.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.6.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.6.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.6.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.7 UK
8.3.7.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.7.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.7.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.7.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.8 France
8.3.8.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.8.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.8.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.8.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.9 Italy
8.3.9.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.9.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.9.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.9.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.10 Spain
8.3.10.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.10.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.10.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.10.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.3.11 Russia
8.3.11.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.3.11.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.11.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.3.11.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4 Asia Pacific
8.4.1 Market Size, By Country 2022-2027 (USD Billion)
8.4.2 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.3 Market Size, By Type, 2022-2027 (USD Billion)
8.4.4 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.5 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4.6 China
8.4.6.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.6.2 Market Size, By Type, 2022-2027 (USD Billion)
8.4.6.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.6.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4.7 India
8.4.7.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.7.2 Market Size, By Type, 2022-2027 (USD Billion)
8.4.7.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.7.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4.8 Japan
8.4.8.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.8.2 Market Size, By Type, 2022-2027 (USD Billion)
8.4.8.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.8.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4.9 Australia
8.4.9.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.9.2 Market size, By Type, 2022-2027 (USD Billion)
8.4.9.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.9.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.4.10 South Korea
8.4.10.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.4.10.2 Market Size, By Type, 2022-2027 (USD Billion)
8.4.10.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.4.10.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.5 Latin America
8.5.1 Market Size, By Country 2022-2027 (USD Billion)
8.5.2 Market Size, By Technology, 2022-2027 (USD Billion)
8.5.3 Market Size, By Type, 2022-2027 (USD Billion)
8.5.4 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.5.5 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.5.6 Brazil
8.5.6.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.5.6.2 Market Size, By Type, 2022-2027 (USD Billion)
8.5.6.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.5.6.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.5.7 Mexico
8.5.7.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.5.7.2 Market Size, By Type, 2022-2027 (USD Billion)
8.5.7.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.5.7.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.5.8 Argentina
8.5.8.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.5.8.2 Market Size, By Type, 2022-2027 (USD Billion)
8.5.8.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.5.8.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.6 MEA
8.6.1 Market Size, By Country 2022-2027 (USD Billion)
8.6.2 Market Size, By Technology, 2022-2027 (USD Billion)
8.6.3 Market Size, By Type, 2022-2027 (USD Billion)
8.6.4 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.6.5 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.6.6 Saudi Arabia
8.6.6.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.6.6.2 Market Size, By Type, 2022-2027 (USD Billion)
8.6.6.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.6.6.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.6.7 UAE
8.6.7.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.6.7.2 Market Size, By Type, 2022-2027 (USD Billion)
8.6.7.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.6.7.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
8.6.8 South Africa
8.6.8.1 Market Size, By Technology, 2022-2027 (USD Billion)
8.6.8.2 Market Size, By Type, 2022-2027 (USD Billion)
8.6.8.3 Market Size, By Disease Indication, 2022-2027 (USD Billion)
8.6.8.4 Market Size, By Route of Administration, 2022-2027 (USD Billion)
Chapter 9 Company Landscape
9.1 Competitive Analysis, 2020
9.2 GlaxoSmithKline plc (UK)
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Positioning
9.2.4 Info Graphic Analysis
9.3 Merck & Co., Inc. (US)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Positioning
9.3.4 Info Graphic Analysis
9.4 Pfizer, Inc. (US)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Positioning
9.4.4 Info Graphic Analysis
9.5 Sanofi SA (France)
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Positioning
9.5.4 Info Graphic Analysis
9.6 CSL Limited (Australia)
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Positioning
9.6.4 Info Graphic Analysis
9.7 Emergent BioSolutions, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Positioning
9.7.4 Info Graphic Analysis
9.8 Johnson & Johnson (US)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Positioning
9.8.4 Info Graphic Analysis
9.9 AstraZeneca plc (UK)
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Positioning
9.9.4 Info Graphic Analysis
9.10 Serum Institute of India Pvt. Ltd. (India)
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Positioning
9.10.4 Info Graphic Analysis
9.11 Other Companies
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Strategic Positioning
9.11.4 Info Graphic Analysis
The Global Infectious Vaccines Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Infectious Vaccines Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS